Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database

INTRODUCTION: Bicalutamide (BIC), a non-steroidal anti-androgen, is FDA-indicated for use in combination with a luteinizing hormone-releasing hormone (LHRH) analog for treatment of Stage D2 metastatic carcinoma of the prostate. Lack of consensus exists regarding the clinical benefit of BIC use, eith...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Adv Ther
Main Authors: Beebe-Dimmer, Jennifer L., Ruterbusch, Julie J., Bylsma, Lauren C., Gillezeau, Christina, Fryzek, Jon, Schultz, Neil M., Flanders, Scott C., Barlev, Arie, Heath, Elisabeth, Quek, Ruben G. W.
Formato: Artigo
Idioma:Inglês
Publicado: Springer Healthcare Communications 2018
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6133134/
https://ncbi.nlm.nih.gov/pubmed/29946798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-018-0738-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares